SPAC1565.03 Antibody

What is SPAC1565.03 and what cellular processes is it involved in?

SPAC1565.03 is likely a protein involved in the regulation of GTPase activity in Schizosaccharomyces pombe (fission yeast). Based on its similarity to SPAC1565.02c, it contains a BCH domain that shares approximately 46% sequence similarity with the BCH domain of human p50RhoGAP (ARHGAP1). The protein plays crucial roles in cellular processes including morphogenesis, cell division, and signal transduction pathways.

To investigate its cellular functions, researchers should employ multiple complementary approaches:

• Subcellular localization studies using immunofluorescence microscopy

• Co-immunoprecipitation experiments to identify binding partners

• Loss-of-function studies combined with phenotypic analysis

• Comparative studies with mammalian homologs such as human p50RhoGAP

When designing experiments to investigate these cellular processes, it's important to consider cell cycle stage and growth conditions, as GTPase-related functions are often context-dependent and tightly regulated during specific cellular events.

How do I verify the specificity of SPAC1565.03 antibody in my experiments?

Verifying antibody specificity is critical for generating reliable experimental results. For SPAC1565.03 antibody, employ the following methodological approaches:

• Western blot validation:

  • Run protein extracts from wild-type cells alongside extracts from SPAC1565.03 deletion mutants

  • Verify that the antibody detects a band of the expected molecular weight only in wild-type samples

  • Include positive control samples with known expression of SPAC1565.03

• Immunostaining validation:

  • Compare immunostaining patterns between wild-type and SPAC1565.03 deletion cells

  • Use preabsorption controls by pre-incubating the antibody with purified antigen

  • Verify that the staining pattern is consistent with expected subcellular localization

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide or recombinant protein

  • Compare results to non-competed antibody samples

  • Specific binding should be blocked by competition

• Cross-reactivity assessment:

  • Test the antibody against closely related proteins (like SPAC1565.02c)

  • Document any observed cross-reactivity for accurate data interpretation

Similar validation approaches have been used successfully for other research antibodies, as demonstrated in the detection of human Caveolin-3 across multiple experimental systems .

What are the recommended applications for SPAC1565.03 antibody?

Based on information from similar research antibodies, SPAC1565.03 antibody would likely be suitable for:

• Western blotting:

  • Use under reducing conditions with appropriate buffer systems

  • Starting dilution of 0.5-1.0 μg/mL is reasonable, though optimization is necessary

  • Include appropriate molecular weight markers to confirm band size

• Immunohistochemistry (IHC):

  • For fixed tissue preparations, heat-induced epitope retrieval may be necessary

  • Starting concentration of 10-15 μg/mL for overnight incubation at 4°C is recommended

  • Similar protocols have been successful for other research antibodies as demonstrated in the detection of Caveolin-3 in human skeletal muscle sections

• Immunofluorescence:

  • Particularly useful for subcellular localization studies

  • Compatible with co-staining with organelle markers

  • Fixation method should be optimized (paraformaldehyde vs. methanol fixation)

• Immunoprecipitation:

  • For protein-protein interaction studies

  • Can be used to isolate native protein complexes

  • May require optimization of lysis conditions to preserve protein interactions

Each application requires specific optimization. Maintain detailed records of all optimization experiments to ensure reproducibility in your research.

What are the optimal storage conditions for maintaining SPAC1565.03 antibody activity?

To maintain optimal activity of research antibodies like SPAC1565.03 antibody, implement the following evidence-based storage practices:

• Temperature conditions:

  • For long-term storage: Aliquot and store at -80°C immediately upon receipt

  • For working stocks: Store at -20°C in a non-frost-free freezer

  • Avoid repeated freeze-thaw cycles (limit to <5 cycles)

• Aliquoting strategy:

  • Prepare multiple small-volume aliquots (10-20 μL) upon receipt

  • Use low-binding microcentrifuge tubes

  • Include date of aliquoting and number of freeze-thaw cycles on each tube

• Buffer considerations:

  • Storage buffer should typically contain:

    • 50% glycerol (cryoprotectant)

    • PBS or TBS (pH 7.2-7.4)

    • 0.02% sodium azide (antimicrobial)

    • 1% BSA (stabilizer)

• Stability monitoring:

  • Periodically test aliquots against a reference standard

  • Document any decrease in activity over time

  • Consider including positive control samples in each experiment

Following these methodological guidelines can significantly extend the useful life of valuable antibody reagents and ensure experimental reproducibility.

How can I use SPAC1565.03 antibody to investigate GTPase regulation pathways?

Based on information about similar proteins like SPAC1565.02c, SPAC1565.03 antibody can be leveraged to study GTPase regulation pathways through several methodological approaches:

• GTPase activity assays:

  • Immunoprecipitate SPAC1565.03 protein using the antibody

  • Assess GAP activity using purified GTPases and measuring GTP hydrolysis rates

  • Compare activity under different cellular conditions or mutations

  Condition	GTPase	GTP Hydrolysis Rate (pmol/min)	Fold Change vs Control
  Control	Rho1	X.XX ± X.XX	1.0
  Treatment A	Rho1	X.XX ± X.XX	X.X
  Treatment B	Rho1	X.XX ± X.XX	X.X

• Co-localization studies:

  • Use dual immunofluorescence with SPAC1565.03 antibody and antibodies against candidate GTPases

  • Analyze spatial and temporal co-localization during different cellular processes

  • Quantify co-localization using Pearson's or Mander's coefficients

• Biochemical interaction mapping:

  • Perform co-immunoprecipitation experiments using SPAC1565.03 antibody

  • Identify binding partners using mass spectrometry

  • Verify direct interactions with candidate GTPases

• Comparative analysis with homologs:

  • Leverage the sequence similarity with human p50RhoGAP (ARHGAP1)

  • Investigate whether SPAC1565.03 can complement mammalian RhoGAP mutants

Similar approaches have been successfully used in SARS-CoV research to identify and characterize protein interactions and their functional implications .

What are the best approaches for using SPAC1565.03 antibody in co-immunoprecipitation experiments?

For optimal co-immunoprecipitation (co-IP) results using SPAC1565.03 antibody, implement the following methodological framework:

• Lysis buffer optimization:

  • Test multiple buffer compositions to preserve protein-protein interactions:

    • Standard buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, protease inhibitors

    • Mild buffer: 20 mM HEPES pH 7.4, 137 mM NaCl, 0.5% CHAPS, protease inhibitors

    • Stringent buffer: 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, protease inhibitors

  • GTPase interactions often require specific buffer conditions, so empirical testing is critical

• Antibody coupling strategies:

  • Direct approach: Couple SPAC1565.03 antibody to protein A/G beads

  • Indirect approach: Add antibody to lysate, then capture with protein A/G beads

  • Covalent coupling: Use cross-linking agents like BS3 or DMP to prevent antibody co-elution

• Experimental controls:

  • Negative controls:

    • Non-specific IgG of the same species and isotype

    • Lysate from SPAC1565.03 knockout cells

  • Validation controls:

    • Input sample (5-10% of lysate)

    • Reciprocal co-IP with antibodies against suspected interacting partners

• GTPase-specific considerations:

  • Include 5 mM MgCl₂ in all buffers to stabilize GTPase conformations

  • Consider adding GTPγS (activating) or GDP (inactivating) to lock GTPases in specific states

  • For weak or transient interactions, consider using chemical cross-linking agents

Similar approaches have been successfully used in virus-host protein interaction studies to characterize binding partners and their functional significance .

How do I troubleshoot non-specific binding when using SPAC1565.03 antibody in immunohistochemistry?

Non-specific binding is a common challenge in immunohistochemistry (IHC). Here's a systematic troubleshooting approach for SPAC1565.03 antibody:

• Epitope retrieval optimization:

  • Test multiple retrieval methods:

    • Heat-induced epitope retrieval (HIER): Citrate buffer (pH 6.0) vs. EDTA buffer (pH 9.0)

    • Enzymatic retrieval: Proteinase K, trypsin, or pepsin at different concentrations

  • Document results in a comparison table:

  Retrieval Method	Signal Intensity	Background	Signal-to-Noise Ratio
  Citrate pH 6.0, 20 min	Low/Medium/High	Low/Medium/High	XX:1
  EDTA pH 9.0, 20 min	Low/Medium/High	Low/Medium/High	XX:1
  Proteinase K, 5 min	Low/Medium/High	Low/Medium/High	XX:1

• Blocking protocol refinement:

  • Test different blocking solutions:

    • 5-10% normal serum (from the same species as secondary antibody)

    • 3-5% BSA in PBS

    • Commercial blocking reagents

  • Include additives to reduce specific causes of background:

    • 0.1-0.3% Triton X-100 for membrane permeabilization

    • 0.1-0.3% glycine to block free aldehyde groups from fixation

• Antibody dilution optimization:

  • Perform systematic dilution series (e.g., 1:100, 1:250, 1:500, 1:1000)

  • Extend incubation time for higher dilutions (overnight at 4°C)

• Validation approaches:

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide

  • Test tissue from knockout organisms as negative control

Similar optimization approaches have been successfully applied for human Caveolin-3 antibody in immunohistochemical applications, resulting in specific staining of sarcolemma in muscle cells with minimal background .

What are the considerations for using SPAC1565.03 antibody in combination with other antibodies for multi-color immunofluorescence?

When designing multi-color immunofluorescence experiments that include SPAC1565.03 antibody, consider these methodological details:

• Antibody compatibility assessment:

  • Host species compatibility:

    • Avoid primary antibodies raised in the same species unless directly labeled

    • If using multiple antibodies from same species, employ sequential staining with blocking steps

  • Create an antibody compatibility matrix:

  Antibody	Host Species	Isotype	Compatible Secondary Antibodies
  SPAC1565.03	Mouse/Rabbit/etc.	IgG1/IgG2a/etc.	Anti-mouse IgG1-Alexa 488, etc.
  Antibody 2	Species	Isotype	Compatible secondaries
  Antibody 3	Species	Isotype	Compatible secondaries

• Spectral considerations:

  • Choose fluorophores with minimal spectral overlap

  • For 3+ color experiments, conduct spectral unmixing controls

  • Consider brightness hierarchy: assign brightest fluorophores to least abundant targets

• Staining sequence optimization:

  • Test sequential vs. simultaneous incubation of primary antibodies

  • For sequential staining, determine optimal order (generally start with lowest abundance target)

  • Include blocking steps between sequential rounds

• Controls for multi-color experiments:

  • Single-color controls for each antibody

  • Secondary antibody-only controls

  • Absorption controls for suspected cross-reactivity

• Quantitative analysis approaches:

  • Co-localization analysis: Pearson's or Mander's coefficients

  • Object-based analysis: Distance between objects or overlap percentage

These considerations align with methodological approaches used in high-quality immunofluorescence studies, as demonstrated in the literature for other research antibodies .

How should I design proper controls when using SPAC1565.03 antibody in my research?

A robust control strategy is essential for generating reliable data with SPAC1565.03 antibody. Here's a comprehensive framework for designing appropriate controls:

• Specificity controls:

  • Genetic controls:

    • SPAC1565.03 knockout/knockdown cells or organisms

    • Overexpression systems with tagged SPAC1565.03

  • Absorption controls:

    • Pre-incubation of antibody with immunizing peptide/protein

    • Titration series of blocking peptide to demonstrate dose-dependent loss of signal

  • Secondary antibody controls:

    • Omission of primary antibody

    • Isotype-matched irrelevant antibody

• Application-specific controls:

  • For Western blotting:

    • Positive control (tissue/cells known to express SPAC1565.03)

    • Loading control (housekeeping protein)

    • Molecular weight markers

  • For immunofluorescence:

    • Counterstains to visualize cellular structures

    • Co-staining with known markers that should or should not co-localize

• Experimental validation matrix:

  Control Type	Purpose	Expected Result	Interpretation if Failed
  Knockout sample	Antibody specificity	No signal	Possible cross-reactivity
  Peptide competition	Epitope specificity	Reduced/absent signal	Non-specific binding
  Secondary only	Background assessment	No signal	High background from secondary
  Positive tissue	Sensitivity validation	Clear signal	Possible sensitivity issues

Similar control strategies have been implemented in antibody validation studies as demonstrated in the literature for Caveolin-3 antibody, where specific bands were detected at the expected molecular weight in human heart and skeletal muscle tissues but not in negative control samples .

What approaches can I use to validate SPAC1565.03 antibody specificity in knockout/knockdown models?

Validating antibody specificity using genetic models is the gold standard approach. For SPAC1565.03 antibody, implement the following methodological framework:

• Generation of genetic validation models:

  • CRISPR/Cas9 knockout:

    • Design guide RNAs targeting early exons of SPAC1565.03

    • Confirm editing by sequencing

    • Establish clonal lines

  • RNA interference:

    • Design siRNA/shRNA targeting SPAC1565.03 mRNA

    • Include scrambled sequence controls

    • Establish stable knockdown lines if needed

• Validation experimental design:

  • Western blot analysis:

    • Run wild-type and knockout/knockdown samples side-by-side

    • Include concentration gradient of wild-type samples

    • Quantify band intensity normalized to loading control

  • Immunofluorescence comparison:

    • Image wild-type and knockout cells under identical conditions

    • Quantify signal intensity across multiple cells/fields

    • Compare subcellular distribution patterns

• Rescue experiments:

  • Re-express SPAC1565.03 in knockout cells

  • Use expression constructs with:

    • Native protein

    • Epitope-tagged versions

Similar validation approaches have been used for other research antibodies, as seen with monoclonal antibodies against SARS-CoV, where specificity was verified through multiple complementary techniques .

How can I quantitatively analyze Western blot data generated using SPAC1565.03 antibody?

For rigorous quantitative analysis of Western blot data using SPAC1565.03 antibody, implement the following methodological framework:

• Experimental design for quantification:

  • Include a standard curve of purified protein or concentration gradient of positive control

  • Run technical replicates (minimum of three)

  • Include appropriate loading controls (housekeeping proteins)

  • Consider using total protein staining methods as alternative loading controls

• Image acquisition parameters:

  • Ensure signal is within linear dynamic range:

    • Avoid saturated pixels

    • Perform exposure series to confirm linearity

  • Use consistent scanner settings across comparative experiments

  • Document all acquisition parameters

• Quantification workflow:

  • Background subtraction methods:

    • Local background (region adjacent to band)

    • Rolling ball algorithm (ImageJ/Fiji)

    • Lane-based background (average intensity of lane excluding bands)

  • Normalization strategies:

    • Ratio to loading control

    • Ratio to total protein

    • Percent of control sample

• Data analysis framework:

  Sample	Raw Signal	Background	Net Signal	Loading Control	Normalized Signal	Fold Change
  Control	XXXX	XXX	XXXX	XXXX	1.00	1.00
  Sample 1	XXXX	XXX	XXXX	XXXX	X.XX	X.XX
  Sample 2	XXXX	XXX	XXXX	XXXX	X.XX	X.XX

• Statistical analysis approaches:

  • For multiple conditions:

    • ANOVA with appropriate post-hoc tests

    • Report effect sizes and confidence intervals

  • For paired comparisons:

    • t-test or non-parametric alternatives

    • Report p-values and confidence intervals

Similar quantitative approaches have been used in the literature for analyzing Western blot data from Human Caveolin-3 antibody experiments, where specific bands were quantified at approximately 20 kDa in human heart tissue, human skeletal muscle tissue, and other relevant samples .

How does SPAC1565.03 compare structurally and functionally to human homologs?

Based on information about the similar protein SPAC1565.02c, we can draw comparative insights about SPAC1565.03 and its potential human homologs:

• Structural comparison:

  • Domain architecture:

    • If SPAC1565.03 is similar to SPAC1565.02c, it likely contains a BCH domain

    • This domain shows approximately 46% sequence similarity to the BCH domain of human p50RhoGAP (ARHGAP1)

    • Key conserved motif: R(R/K)h(R/K)(R/K)NL(R/K)xhhhhHPs, where "h" represents large hydrophobic residues and "s" represents small weakly polar residues

  Protein	Domain Architecture	BCH Domain Conservation (%)	GAP Domain Present?
  SPAC1565.03	[Predicted based on homology]	[Estimated]	[Predicted]
  SPAC1565.02c	N-terminal BCH, C-terminal GAP	100% (reference)	Yes
  Human ARHGAP1	N-terminal BCH, C-terminal GAP	~46% to SPAC1565.02c	Yes

• Functional comparison methodology:

  • GTPase specificity profiling:

    • Compare GTPase substrate preferences between yeast and human proteins

    • Measure GAP activity using purified components

  • Complementation studies:

    • Express human homologs in SPAC1565.03 deletion strains

    • Assess rescue of phenotypes

    • Quantify degree of functional conservation

• Evolutionary conservation analysis:

  • Phylogenetic tree construction:

    • Include SPAC1565.03, SPAC1565.02c, and human RhoGAP proteins

    • Identify key evolutionary branches and potential functional divergence

  • Structure-function relationship:

    • Map conserved residues to protein structures

    • Predict critical functional sites

Similar comparative approaches have been used to understand functional relationships between viral proteins and their interactions, as seen in SARS-CoV research with monoclonal antibodies .

What are the best practices for analyzing contradictory results when using SPAC1565.03 antibody across different experimental conditions?

When faced with contradictory results using SPAC1565.03 antibody across different experimental conditions, implement this systematic troubleshooting framework:

• Technical validation strategy:

  • Antibody performance assessment:

    • Re-validate antibody specificity using controls

    • Test new lot of antibody if available

    • Compare with alternative antibodies targeting different epitopes

  • Protocol standardization:

    • Document exact protocols with all parameters

    • Systematically vary one condition at a time

  Parameter	Condition A	Condition B	Outcome A	Outcome B	Potential Cause of Discrepancy
  Buffer pH	7.2	8.0	Result X	Result Y	Epitope sensitivity to pH
  Fixation	PFA	Methanol	Result X	Result Y	Epitope masking by fixation
  Cell type	Type 1	Type 2	Result X	Result Y	Differential PTMs or isoforms

• Biological interpretation framework:

  • Context-dependent protein behavior:

    • Post-translational modifications affecting epitope accessibility

    • Protein conformational changes under different conditions

    • Protein interaction partners masking antibody binding sites

  • Expression level variations:

    • Cell cycle-dependent expression

    • Stress-induced changes

    • Tissue-specific regulation

• Reconciliation approaches:

  • Orthogonal validation methods:

    • Mass spectrometry validation

    • RNA-level analysis (qPCR, RNA-seq)

    • Functional assays

Similar approaches have been employed in SARS-CoV antibody research when analyzing variable results across different experimental systems and viral strains .

How can I use the Patent and Literature Antibody Database (PLAbDab) to find related antibodies for comparative studies?

Based on search result information about PLAbDab , this database represents a valuable resource for researchers working with antibodies like SPAC1565.03 antibody. Here's a methodological framework for leveraging this database:

• Search strategies for finding related antibodies:

  • Sequence-based searches:

    • Use SPAC1565.03 antibody sequence (if available) as query

    • Search by complementarity-determining regions (CDRs)

    • Find antibodies with similar binding characteristics

  • Target-based searches:

    • Search by target protein name or aliases

    • Use related protein terms (e.g., "RhoGAP," "BCH domain")

    • Include target protein sequences for BLAST-like searches

• Database filtering parameters:

  • Source filtering:

    • Filter by species (e.g., mouse, rabbit, human)

    • Select specific antibody formats (e.g., IgG, Fab, scFv)

    • Filter by specific literature types (academic vs. patent)

  • Functional filtering:

    • Filter by reported applications (e.g., WB, IF, IP)

    • Select by epitope location if known

• Comparative analysis framework:

  Parameter	SPAC1565.03 Ab	Related Ab 1	Related Ab 2	Implications
  Epitope region	[Region]	[Region]	[Region]	Epitope coverage
  Applications	WB, IF, etc.	[Apps]	[Apps]	Methodological options
  Cross-reactivity	[Profile]	[Profile]	[Profile]	Specificity considerations
  Species reactivity	[Species]	[Species]	[Species]	Model system options

• Strategic implementation for research:

  • Complementary antibody panels:

    • Select antibodies recognizing distinct epitopes

    • Design validation experiments using multiple antibodies

  • Alternative methodologies:

    • Identify antibodies validated for techniques not yet tested

    • Adapt protocols from literature using related antibodies

PLAbDab contains over 150,000 paired antibody sequences and 3D structural models, of which over 65,000 are unique, making it a comprehensive resource for finding related antibodies for comparative studies .